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This study investigated the effects of nanosuspension and inclusion complex techniques on in vitro 
trypsin inhibitory activity of naproxen—a member of the propionic acid derivatives, which are a group 
of antipyretic, analgesic, and non-steroidal anti-inflammatory drugs. Nanosuspension and inclusion 
complex techniques were used to increase the solubility and anti-inflammatory efficacy of naproxen. 
The evaporative precipitation into aqueous solution (EPAS) technique and the kneading methods were 
used to prepare the nanosuspension and inclusion complex of naproxen, respectively. We also used 
an in vitro protease inhibitory assay to investigate the anti-inflammatory effect of modified naproxen 
formulations. Physiochemical properties of modified naproxen formulations were analyzed using UV, 
IR spectra, and solubility studies. Beta-cyclodextrin inclusion complex of naproxen was found to have 
a lower percentage of antitryptic activity than a pure nanosuspension of naproxen did. In conclusion, 
nanosuspension of naproxen has a greater anti-inflammatory effect than the other two tested formulations. 
This is because the nanosuspension formulation reduces the particle size of naproxen. Based on these 
results, the antitryptic activity of naproxen nanosuspension was noteworthy; therefore, this formulation 
can be used for the management of inflammatory disorders.
Uniterms: Naproxen/nanosuspension/anti-inflammatory activity. Naproxen/inclusion complex/anti-
inflammatory activity. Naproxen/solubility. Protease inhibition.
O objetivo do presente estudo foi investigar a atividade anti-inflamatória in vitro de nanossuspensões e 
do complexo de inclusão contendo naproxeno. Esse fármaco é derivado de ácido propiônico, com ação 
analgésica, antipirética e antiinflamatória. A obtenção dessas formulações teve por finalidade o aumento 
da solubilidade e da atividade anti-inflamatória do fármaco. Os métodos por precipitação em solução 
aquosa por evaporação e por empastagem foram modificados para a obtenção da nanossuspensão e do 
complexo de inclusão, respectivamente. Para a avaliação da atividade anti-inflamatória das formulações 
utilizou-se ensaio in vitro modificado de inibição de tripsina. As propriedades físico-químicas das 
formulações propostas foram determinadas utilizando espectroscopia UV e de infravermelho, além de 
estudos de solubilidade. O complexo de inclusão de naproxeno apresentou menor atividade antitripsina, 
quando comparado ao composto livre e à nanossuspensão. Em conclusão, entre as formulações avaliadas, 
a nanossuspensão de naproxeno apresentou maior efeito anti-inflamatório. Esse efeito foi devido à redução 
da dimensão das partículas de naproxeno para a escala nanométrica. Com base nos resultados obtidos, a 
atividade da nanossuspensão de naproxeno foi notável. Dessa forma, essa formulação apresenta potencial 
para o tratamento de distúrbios inflamatórios.
Unitermos: Naproxeno/nanossuspensão/atividade anti-inflamatória. Naproxeno/complexo de inclusão/
atividade anti-inflamatória. Naproxeno/solubilidade. Inibição da protease.
INTRODUCTION
Naproxen is a stereochemically pure (dextrorotary 
isomer of 6-methoxy-α-methyl-2-naphthalene acetic acid) 
no steroidal anti-inflammatory drug of the 2-arylpropionic 
acid class (Davies,Anderson, 1997). In humans, it 
is oxidised to 6-O-desmethylnaproxen, and both the 
parent drug and metabolite are conjugated as acyl 
glucuronides (Todd, Clissold, 1990). Naproxen has 
been extensively used during the past decades in the 
treatment of rheumatoid arthritis, febrile syndrome, and 
pain (Davies,Anderson, 1997). Naproxen, like most 
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other non-steroidal anti-inflammatory agents, inhibits 
prostaglandin synthesis and thromboxanes (Vane, 1971). 
Both PGE2 and PGI2 markedly enhance edema formation 
and leukocyte infiltration by promoting blood flow in an 
inflamed region. Systemic inhibition of COX leads to 
decreased production of PGs at inflammation sites and 
in the spinal cord. Naproxen is also indicated to relieve 
the signs and symptoms of tendonitis, bursitis, and acute 
gout, as well as to manage pain and primary dysmenorrhea. 
The inhibition of COX-2 is mainly thought to mediate the 
antipyretics, analgesic, and anti-inflammatory action of 
naproxen (Setiawati et al., 2009). However, the naproxen 
action mechanism is not completely understood. It is a 
very potent member of the propionic acid derivatives, 
which represent a group of effective, useful antipyretic, 
analgesic, and non-steroidal anti-inflammatory drugs.
There have not been many strategies to enhance the 
solubility of naproxen. Polyoxyethylene esters as dermal 
prodrugs (Bonina et al., 2001), acyloxyalkyl esters (Rautio 
et al., 1998), and supramolecular carrier systems (Hector 
et al., 2007) with naproxen have been reported.
Proteases are involved in many essential intracellular 
and extracellular physiological processes, but their 
critical role in the development of diseases is also well 
established. Recent developments in the field of proteinase 
have led researchers to inquire closely into their exact 
biological functions. There is now substantial evidence 
that certain proteases can regulate target cells by cleaving 
and activating a family of G-protein-coupled, protease-
activated receptors (PARs). Potential roles for PARs in 
inflammation have also been proposed. For example, 
because platelets can produce inflammatory mediators, 
such as serotonin and chemokines, platelet activation 
by thrombin through PAR1 might amplify inflammatory 
responses or recruitment of inflammatory cells (Coughlin, 
2000). These potential pro-inflammatory effects of trypsin-
like proteases raise two important questions—whether and 
how these proteases affect inflammatory cell functions 
(Lee et al., 1984). Therefore, proteases are perhaps the 
largest class of enzymes to be used as targets for structure-
based drug design. Recent studies have demonstrated that 
protease inhibitors may have anti-inflammatory roles 
other than mere suppressive effects on protease actions 
during inflammation. Currently, trypsin is used routinely 
for preparing keratinocyte cultures from epidermal sheets 
or for splitting confluently grown cells in vitro. In vivo, 
trypsin, and other fecal enzymes cause skin irritation and 
may play an etiologic role in perianal, circumstomal, 
and diaper dermatitis. The hallmarks of these diseases 
are inflammation and epidermal hyperproliferation. 
In an earlier study, we raised the question of whether 
trypsin, as an exemplary serine protease capable of 
activating PAR-2 (and in higher concentrations, PAR-1), 
induces epidermal changes (Meyer-Hoffert et al., 2004). 
Therefore, this investigation sought to assess the effects of 
nanosuspension and inclusion complex techniques on the 
in vitro protease inhibitory activity of naproxen.
MATERIAL AND METHODS
Drugs and Chemicals 
Naproxen (Ezo Life Sciences, CAS 22204-53-1), 
carboxymethyl cellulose (CMC), hydroxypropylmethyl 
cellulose (HPMC), poly(vinyl alcohol) (PVA), methanol, 
ethyl acetate, sodium chloride, disodium hydrogen 
phosphate, trypsin, tris hydrochloride (Tris-C1), casein, 
triethanolamine, cellulose nitrate membrane, and isopropyl 
myristate were supplied by Sigma-Aldrich. All other 
chemicals and solvents used were commercially available 
products of analytical grade. A Shimadzu UV-1800 UV/
VIS spectrophotometer was used with a 1 cm match quartz 
cell, and a CP224S analytical balance (Sartorius) and ultra-
sonic cleaner (Fisher Scientific FB15061) were used. A 
micropipette with a variable volume of 10-1000 μL (Capp 
Ecopipette single channel) and a digital balance (Mettler 
Toledo XP 105) were also used.
EPAS Preparation of the Nanosuspension
The Evaporative Precipitation into Aqueous 
Solution (EPAS) technique was used to produce a 
nanoparticle suspension of naproxen. When a heated 
organic solution of the drug is sprayed though a fine nozzle 
into a heated aqueous solution, the rapid evaporation of 
the organic solvent produces high supersaturation and 
rapid precipitation of the drug in the form of a colloidal 
suspension that is stabilized by a variety of low molecular 
weight and polymeric surfactants. The stabilizer adsorbs 
to the drug surface and prevents particle growth and 
crystallization during the spraying process (Chen, 2002; 
Sarkari, 2002). A weighed amount of naproxen was 
dissolved in 10 mL of ethyl acetate. The resultant solution 
is then sprayed though a fine nozzle into a heated aqueous 
solution at 80-85 oC containing stabilizing surfactant 
and polysorbate 80. The mixture is then continuously 
stirred magnetically. Ethyl acetate is allowed to evaporate 
forming the nanosuspension. The rapid evaporation of 
the organic solvent produces high supersaturation and 
rapid precipitation of the drug in the form of a colloidal 
suspension. Last, the colloidal suspension is centrifuged 
and freeze dried.
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Preparation of Inclusion Complex by the Kneading 
Method
A weighed quantity of β-cyclodextrin (β-CD) was 
mixed with a minimum quantity of distilled water in a 
mortar to obtain a homogeneous paste. A weighed quantity 
of naproxen powder was then slowly added. After that, 
the mixture was ground for 1 hour. During this process, 
an appropriate quantity of water was added to the mixture 
to maintain a pasty consistency. The whole procedure 
was carried out at room temperature. The paste was then 
oven dried at 45 °C for 24 hours. The dried complex was 
pulverized, and it then was passed through a #100 sieve 
and stored in a desiccator over fused calcium chloride 
pending further study. The complexes were prepared in 
both 1:1 and 1:2 molar ratios (Sapkal et al., 2010).
UV Analysis
The maximum absorption value for the naproxen 
was found to be 331 nm using the UV spectrophotometric 
method. The linear regression equation obtained by the 
least square regression method was y= 0.0108 X - 0.028 
with a correlation coefficient of 0.9984 where y is the 
absorbance and x is the concentration of the pure naproxen 
solution. The method was validated for several parameters 
such as linearity, accuracy (recovery), precision, and 
specificity under the International Conference on 
Harmonization (ICH) guidelines. The limits of detection 
(LOD) and quantification (LOQ) were 1.53 μg/mL and 
5.11 mg/mL, respectively.
Solubility Determination
The solubility of pure naproxen, nanosuspension of 
naproxen, and inclusion complex with a 1:2 molar ratio 
(a 50 mg equivalent amount ) were analysed by adding 
naproxen to 10 mL of each fluid in a 25 mL stopped conical 
flask after which the mixtures were shaken for 24 hours 
at room temperature (25±1°C) on a rotary shaker. After 
24 hours of shaking, 2 mL aliquots were withdrawn at 
two-hour intervals and immediately filtered using a 0.45 μ 
disk filter. The filtered samples were diluted suitably and 
analysed by a UV UV/VIS spectrophotometer at 331 nm. 
Each solubility experiment was replicated three times 
(n=3) (Chowdary, Surya Prakasa Rao, 2011).
Infrared (IR) Spectra for Cyclodextrin Inclusion 
Complex
Studies were done by Fourier using infrared 
spectroscopy (FTIR-8300, Shimadzu Co., Kyoto, Japan) 
and scanned against a blank KBr pellet background at 
a wave number ranging from 4000 to 650 cm-1 with a 
resolution of 1.0 cm-1 (Sapkal et al., 2010).
In vitro Protease (Trypsin) Inhibitory Activity
The antitryptic activity of the pure naproxen, 
nanosuspension of naproxen, and inclusion complex with 
a 1:2 molar ratio were assayed by the method previously 
described (Anantha et al., 1956). The reaction mixture 
(2.0 mL) contained 0.06 mL trypsin (0.6 µg), varying 
volumes of modified naproxen formulations, and a 25 mM 
Tris-C1 buffer, pH 7.5. The mixture was incubated at 37 °C 
for 5 minutes. Then, 1 mL of 0.8% (w/v) casein was added. 
The mixture was incubated for an additional 20 minutes 
and 2 mL of 2 M HClO4 were added to terminate 
the reaction. The cloudy suspension was clarified by 
centrifugation and the absorbance of the supernatant was 
read at 280 nm against the buffer as blank.
RESULTS AND DISCUSSION
FTIR Spectra Analysis
Characteristic peaks at 1820-1670 cm -1 were 
observed due to the presence of C=O stretching, which 
is the important characteristic of naproxen (Figure 1.a). 
This suggested that the aromatic structure (non-polar) 
of naproxen is entrapped inside the cyclodextrin cavity 
while the carboxylic acid group still remains outside the 
cyclodextrin cavity. Hence, C=O stretching at 1728 cm-1 
is observed in the IR spectra of the inclusion complex 
(Figures 1 and 2).
 
Solubility studies 
The  so lub i l i ty  p rof i l e  o f  pure  naproxen , 
nanosuspension, and naproxen-cyclodextrin complex is 
shown in Figure 3. The solubility using beta-cyclodextrin 
techniques is better than that using the nanosuspension 
technique. β-Cyclodextrin inclusion complex of naproxen 
in a 1:2 ratio showed the highest percentage of dissolved 
drug, which was 10 times higher than plain naproxen, while 
the solubility nanosuspension technique is 3 times higher 
than that for plain naproxen.The increased surface area and 
concentration gradient lead to a much more pronounced 
increase in the solubility of nanosuspension as compared 
to that for a pure drug. The diffusional distance of drug 
nanoparticles on the surface is decreased, thus leading to 
an increased concentration gradient (Muller, Peters, 1998).
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Anti-protease inhibitory activity
Proteases have been implicated in tumourigenesis, 
invasive growth, alteration of cellular surface charges, 
and the release of cells from density-dependent inhibition 
(Techesche et al., 1974). Conversely, removal of protease 
activity from the sites of inflammation or blockade 
of eosinophil PARs may benefit patients with allergic 
diseases by dampening this vicious cycle of allergic 
inflammation. Recent studies have demonstrated that 
protease inhibitors may have anti-inflammatory roles 
other than mere suppressive effects on protease actions 
during inflammation. A number of mediators, including 
lipid mediators, cytokines, free radicals, complement 
fragments, coagulatory factors, and proteases contribute 
to the pathogenesis of endotoxin shock (Bhole, Stahl, 
FIGURE 1 - IR spectra of plain naproxen.
FIGURE 2 - IR spectra of naproxen-cyclodextrin complex.
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FIGURE 4 -In vitro antitryptic activity of different naproxen formulations. Values are expressed as the mean ± SEM of triplicate 
experiments.
2003). Among them, the products from neutrophils are 
recognized to play important roles. Activated neutrophils 
release various kinds of mediators, including proteases and 
oxygen radicals (Weiss, 1989). The proteases produced by 
neutrophils can be a key mediator of tissue injury (Travis, 
1988). Protease-antiprotease imbalance has been involved 
in a variety of inflammatory diseases (Chapman et al., 
1997; Deng et al., 2001).
It is also evident that the inclusion complex method 
exhibits a higher solubility profile than nanosuspension 
and the plain drug do (Figure 3). This enhancement has 
been attributed in all these cases both to the formation of 
an inclusion complex in the solid state and to the reduction 
of the crystalinity of the products.
The trypsin inhibitory effect of naproxen and its 
modified formulations is shown in Figure 4. Universally, 
naproxen has established anti-inflammatory effects. It is 
a trypsin inhibitor that acts as a competitive analog and 
binds with its serine protease to form an inactive complex, 
rendering the protease inactive, thus acting as an anti-
inflammatory agent (Reddy et al., 2003; Caramori et al., 
2004). The two modified formulations and pure naproxen 
exhibited varying degrees of trypsin inhibitory activity. 
Nanosuspension of naproxen exhibit the highest antitryptic 
FIGURE 3 -The solubility of different naproxen formulations in distilled water. Values are expressed as the mean ± SEM of triplicate 
experiments.
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activity, which was 1.5 times higher than that of plain 
naproxen. This suggested that nanosuspension of naproxen 
has greater anti-inflammatory effect than the other 
formulations. The antitryptic effects of nanosuspension 
are significantly different from those of plain naproxen. 
In nanosuspension, the reduced particle size of naproxen 
will increase the surface area and number of particles. In 
turn, this will lead to more extensive antitryptic activity as 
more trypsin breaks down due to its enhanced solubility 
profile compared to that of plain naproxen. However, 
β-cyclodextrin inclusion complex showed the lowest anti-
inflammatory activity when compared to the inclusion 
complex formulation, which was encapsulated in the 
cavity of β-cyclodextrin and unable to interact with trypsin 
to form an inactive naproxen-trypsin complex responsible 
for an anti-inflammation reaction.
Poor solubil i ty can be part ly attr ibuted to 
hydrophobicity as evidenced by poor wetting of the drug 
surface. This causes the particles to aggregate rather than 
disperse. The solubility profile in the nanosuspension was 
improved because of the increased surface area, which 
enhances the strong hydrophilic character of the drug 
toward polysorbate 80. This is because of the formation of 
intermolecular hydrogen bonds and improved wettability 
of hydrophobic naproxen. Saturation solubility is 
compound specific constant depending upon temperature 
and the properties of the dissolution medium.
β-Cyclodextrin inclusion complex of naproxen has 
a lower percentage of antitryptic activity than both plain 
naproxen and nanosuspension of naproxen. Nevertheless, 
the difference of antitryptic activity between beta-
cyclodextrin inclusion complex of naproxen and plain 
naproxen is not significant when the p value is greater 
than 0.05. Hence, this result shows that beta-cyclodextrin 
inclusion complex does not increase the anti-inflammation 
activity of naproxen. This suggests that the large molecules 
of the inclusion complex were unable to form an inactive 
complex with trypsin, which in turn reduced the inhibitory 
effect of naproxen towards trypsin. Thus, it does not 
improve the anti-inflammatory effect of naproxen. In 
conclusion, nanosuspension naproxen has greater anti-
inflammatory effect than the other two formulations. This 
is because the nanosuspension formulation has reduced the 
particle size of naproxen, thus increasing the surface area 
and number of naproxen particles. Hence, this leads to a 
greater extent of anti-proteolytic activity.
CONCLUSION
The Nanosuspension and inclusion complex 
technique were prepared and showed that they better 
enhance solubility in comparison to pure naproxen’s 
solubility. Based on these results, the antitryptic activity of 
naproxen nanosuspension was noteworthy. These findings 
appear to justify the nanosuspension of naproxen in the 
management and treatment of inflammation-associated 
ailments. The new formulation based on the nanosuspension 
technique can be adapted to enhance solubility and the 
antitryptic activity of drugs with poor water solubility.
REFERENCES
ANANTHASAMY, T.S.; NATARAJAN, S.; CAMA, H.R. 
Physiochemical and biological properties of glycoproteins 
isolated from the plasma of different species of animals. 
Biochem. J., v.96, p.281-288, 1965.
BHOLE, D.; STAHL, G.L. Therapeutic potential of targeting the 
complement cascade in critical care medicine. Crit. Care 
Med., v.31, suppl.1, p.S97-S104, 2003.
BONINA, F.P. ;  PUGLIA, C.;  BARBUZZI,  T.P. ;  DE 
CAPRARIIS, F.; PALAGIANO, M.G.; RIMOLI SAIJA, 
A. In vitro and in vivo evaluation of polyoxyethylene esters 
as dermal prodrugs of ketoprofen, naproxen and diclofenac. 
Eur. J. Pharm. Sci., v.14,p.123-134, 2001.
CARAMORI, S.S.; LIMA, C.S.; FERNANDES, K.F. 
Biochemical characterization of selected plant species 
from Brazilian savannas. Braz. Arch. Biol. Techn., v.47, 
p.253-259, 2004.
CHAPMAN, H.A.; RIESE, R.J.; SHI, G.P. Emerging roles for 
cysteine proteases in human biology. Annu. Rev. Physiol., 
v.59, p.63-88,1997.
CHEN, X.; YOUNG, T.J.; SARKARI, M.; WILLIAMS, R.O.; 
JOHNSTON, K.P. Int. J. Pharm., v.242, p.3-14, 2002.
CHOWDARY, K.P.R.; SURYA PRAKASA RAO, K. Factorial 
studies on the effects of β- cyclodextrin and poloxamer 407 
on the solubility and dissolution rate of BCS class II drugs. 
Int. J. Pharm. Res. Dev., v.3, p.125-130, 2011.
COUGHLIN, S.R. Thrombin signalling and protease-activated 
receptors. Nature, v.407, p.258, 2000.
DAVIES, N.M.; ANDERSON, K.E. Clinical pharmacokinetics 
of naproxen. Clin. Pharmacokinet.,v.32, p.268-293, 1997.
Effects of nanosuspension and inclusion complex techniques on the in vitro protease inhibitory activity of naproxen 171
DENG, X.; WANG, X.; LASSON, A.; SUN, T.Z.; SOLTESZ, V.; 
ANDERSSON, R. The involvement of multiple protease-
antiprotease systems and gut origin sepsis in zymosan-
associated endothelial barrier injury and multiple organ 
dysfunction in rats. Shock, v.16, p.298-303, 2001.
HECTOR L.R.; AYMARA, V.; ROBERTO, C.; ALEX, 
F.; JUAN JOSE, T.L.; MAYSA, B.; REYNALDO, V. 
Preparation of β-cyclodextrin-dextran polymers and their 
use as supramolecular carrier systems for naproxen. Polym. 
Bull.,v.59, p.597-605, 2007.
INOUE, K.; TAKANO, H.; SHIMADA, A.; YANAGISAWA, R.; 
SAKURAI, M.; YOSHINO, S.; SATO, H.; YOSHIKAWA, 
T. Urinary trypsin inhibitor protects against systemic 
inflammation induced by lipopolysaccharide. Mol. 
Pharmacol., v.67, p.673-680, 2005.
INTERNATIONAL CONFERENCE ON HARMONISATION.
Harmonized tripartite guidelines. Stability testing of new 
drug substances and products. ICH Committee, v.68, 
p.65717-65718, 2003. Available at: www.ich.org/fileadmin/ 
Public_Web_Site/ICH_Products/Guidelines/Quality/
Q1A_R2/Step4/Q1A_R2__Guideline.pdf. Accessed on: 
23 Aug. 2012.
LEE, T.; LENIHAN, D.J.; MALONE, B.; RODDY, L.L.; 
WASSERMAN, S.I. Increased biosynthesis of platelet-
activating factor in activated human eosinophils. J. Biol. 
Chem., v.259, p.5526-5530, 1984.
MEYER-HOFFERT, U.; HRISTINA-ROGALSKI, C.; 
SEIFERT, S.; SCHMELING, G.; WINGERTSZAHN, J.; 
PROKSCH, E.; WIEDOW, O. Trypsin induces epidermal 
proliferation and inflammation in murine skin. Exp. 
Dermatol., v.13, p.234-241, 2004.
MIIKE, S.; MCWILLIAM, A.S.; KITA, H. Trypsin induces 
activation and inflammatory mediator release from human 
eosinophils through protease-activated receptor-2. J. 
Immunol., v.167, p.6615-6622, 2001.
MULLER, R.H.; PETERS, K. Nanosuspensions for the 
formulation of poorly soluble drug I: Preparation by size 
reduction technique. Int. J. Pharm., v.160, p.160, 229-237, 
1998.
RAUTIO, J.; TAIPALE, H.; GYNTHER, J.; VEPSAELAEINEN, 
J.; NEVALAINEN, T.; JAERVINEN, T. In vitro evaluation 
of acyloxyalkyl esters as dermal prodrugs of ketoprofen and 
naproxen. J. Pharm. Sci., v.87,p.1622-1628, 1998.
REDDY, N.S.; GEURS, N.C.; GUNSOLLEY, J.C. Periodontal 
host modulation with antiproteinase, anti-inflammatory and 
bone-sparing agents. Ann. Periodontol., v.8, p.12-37, 2003.
SAPKAL, N.P.; VAISHALI, A.K.; SHEWALE, B.D.; 
BHUSARI, K.P.; DAUD, A.S. Study of the complexation 
behaviour of fexofenadine with β-cyclodextrin. Indian J. 
Pharm. Sci., v.72, p.318-323, 2010.
SARKARI, M.; BROWN, J.N.; CHEN, X.; SWINNEA, S.; 
WILLIAMS, R.O.; JOHNSTON, K.P. Int. J. Pharm., v.243, 
p.17-31, 2002.
SETIAWATI,  E. ;  DENIATI,  S.H.;  YUNAIDI,  D.A.; 
HANDAYANI, L.R.; HARINANTO, G.; SANTOSO, I.D.; 
PURNOMO SARI, A.; RIMAINAR, A. Bioequivalence 
study with two naproxen sodium tablet formulations in 
healthy subjects. J. Bioequiv. Availab., v.1, p.28-33, 2009.
TECHESCHE, N.; KUPFER, S.; LENGEL, O.; KLAUSER, 
R. Purification, characterization and structural studiesof 
proteinase inhibitors from boar seminal plasma and boar 
spermatozoa. Buyer Symposium,v.5, p.164-177, 1974.
TODD, P.A.; CLISSOLD, S.P. Naproxen- A reappraisal of its 
pharmacology and its therapeutic use in rheumatic diseases 
and pain states. Drugs, v.40, p.91-137, 1990.
TRAVIS, J. Structure, function and control of neutrophil 
proteinases. Am. J. Med., v.84, p.37-42, 1988.
VANE, J.R. Inhibition of prostaglandin synthesis as a 
mechanism of action of aspirin-like drugs. Nat. New Biol., 
v.231, p.232-235, 1971.
WEISS, S.J. Tissue destruction by neutrophils. N. Engl. J. Med., 
v.320, p.365-376, 1989.
Received for publication on 23rd August 2012
Accepted for publication on 12th May 2013

